Clinical Trial

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to preliminarily explore the efficacy and safety of Iparomlimab and Tuvonralimab in combination with Nimotuzumab for the treatment of recurrent/metastatic nasopharyngeal carcinoma (NPC). It is expected to investigate a novel therapeutic regimen with improved efficacy and enhanced safety for recurrent/metastatic NPC, thereby providing robust evidence-based medical support for the application of dual-target immune checkpoint inhibitors in nasopharyngeal carcinoma therapy
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-31.
Status change: Not Yet Recruiting → Recruiting 2026-01-21
Trial Details
NCT Number NCT07101744
Lead Sponsor Sun Yat-sen University
Conditions Nasopharyngeal Carcinoma (NPC), First-line Treatment Failure Nasopharyngeal Carcinoma
Enrollment 41 participants
Start Date 2025-10-17
Primary Completion 2028-07-16 (estimated)
Study Completion 2030-07-16 (estimated)
Updated on ClinicalTrials.gov 2026-01-23